Molecular Imaging of Reporter Gene Expression in Prostate Cancer: An Overview

Seminars in Nuclear Medicine

Volumn 38, Issue 1, 2008, Pages 9-19

  Singh, Abhinav ^a   Massoud, Tarik F ^b   Deroose, Christophe ^c   Gambhir, Sanjiv S ^d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO 4 NITROPHENOL; 2 FLUORO 4 NITROPHENYL BETA DEXTRO GALACTOPYRANOSIDE; ANTINEOPLASTIC AGENT; FLUC PROTEIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FLUTAMIDE; HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE; KALLIKREIN; KALLIKREIN 2; MITOMYCIN C; NITROPHENOL; PERTECHNETIC ACID TC 99M; PROSTATE STEM CELL ANTIGEN; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER DIAGNOSIS; CANCER THERAPY; CYTOLOGY; DIAGNOSTIC ACCURACY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEALTH HAZARD; HUMAN; MOLECULAR IMAGING; NONHUMAN; PROSTATE CANCER; REPORTER GENE; REVIEW;

DIAGNOSTIC IMAGING; GENES, REPORTER; HUMANS; MALE; MOLECULAR PROBE TECHNIQUES; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37149000959     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.09.002     Document Type: Review

References (77)

1. Chokkalingam A.P., Stanczyk F.Z., Reichardt J.K., et al. Molecular epidemiology of prostate cancer: Hormone-related genetic loci. Front Biosci 12 (2007) 3436-3460
2. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 175 (2007) 1-8
3. Delongchamps N.B., Singh A., and Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13 (2006) 158-168
4. Tsakiris P., and de la Rosette J. Imaging in genitourinary cancer from the urologists' perspective. Cancer Imaging 7 (2007) 84-92
5. Norberg M., Egevad L., Holmberg L., et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50 (1997) 562-566
6. Hricak H., Choyke P.L., Eberhardt S.C., et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology 243 (2007) 28-53
7. Yu K.K., and Hricak H. Imaging prostate cancer. Radiol Clin North Am 38 (2000) 59-85
8. Massoud T.F., and Gambhir S.S. Integrating noninvasive molecular imaging into molecular medicine: An evolving paradigm. Trends Mol Med 13 (2007) 183-191
9. Jaffer F.A., and Weissleder R. Molecular imaging in the clinical arena. JAMA 16 (2005) 855-862
10. Gross S, Piwnica-Worms D: Molecular imaging strategies for drug discovery and development. Curr Opin Chem Biol 10:334-342
11. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
12. Effert P.J., Bares R., Handt S., et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
13. Fanti S., Nanni C., Ambrosini V., et al. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging 51 (2007) 260-271
14. Lawrentschuk N., Davis I.D., Bolton D.M., et al. Positron emission tomography and molecular imaging of the prostate: An update. BJU Int 97 (2006) 923-931
15. Karam J.A., Mason R.P., Koeneman K.S., et al. Molecular imaging in prostate cancer. J Cell Biochem 90 (2003) 473-483
16. Powles T., Murray I., Brock C., et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 (2007) 1511-1520 discussion 1520-1511
17. Procissi D., Claus F., Burgman P., et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 13 (2007) 3738-3747
18. Katz S., and Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 44 (2006) 723-734 viii
19. Vilanova J.C., and Barcelo J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom Imaging 32 (2007) 253-261
20. Goeb K., Engehausen D.G., Krause F.S., et al. MRI spectroscopy in screening of prostate cancer. Anticancer Res 27 (2007) 687-693
21. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
22. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97 (2000) 9226-9233
23. Gambhir S.S., Barrio J.R., Herschman H.R., et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 26 (1999) 481-490
24. Alam J., and Cook J.L. Reporter genes: Application to the study of mammalian gene transcription. Anal Biochem 188 (1990) 245-254
25. Serganova I., and Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl Med Biol 32 (2005) 763-780
26. Massoud TF: In vivo molecular imaging in oncology: Principles of reporter gene expression imaging, in Hayat MA (ed): Cancer Imaging, Vol. 2: Instrumentation and Applications. Philadelphia, Elsevier (in press)
27. Doubrovin M., Ponomarev V., Beresten T., et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA 98 (2001) 9300-9305
28. Green L.A., Yap C.S., Nguyen K., et al. Indirect monitoring of endogenous gene expression by positron emission tomography (PET) imaging of reporter gene expression in transgenic mice. Mol Imaging Biol 4 (2002) 71-81
29. Contag C.H., and Bachmann M.H. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4 (2002) 235-260
30. Brenner M. Gene marking. Hum Gene Ther 7 (1996) 1927-1936
31. Qian D.Z., Ren M., Wei Y., et al. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 64 (2005) 20-28
32. Jenkins D.E., Yu S.F., Hornig Y.S., et al. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20 (2003) 745-756
33. Iyer M., Salazar F.B., Lewis X., et al. Noninvasive imaging of enhanced prostate- specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 10 (2004) 545-552
34. Ilagan R., Zhang L.J., Pottratz J., et al. Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther 4 (2005) 1662-1669
35. Zhang L., Johnson M., Le K.H., et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 63 (2003) 4552-4560
36. Seethammagari M.R., Xie X., Greenberg N.M., et al. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 66 (2006) 6199-6209
37. El Hilali N., Rubio N., Martinez-Villacampa M., et al. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest 82 (2002) 1563-1571
38. Yang H., Berger F., Tran C., et al. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate 55 (2003) 39-47
39. Chemaly E.R., Yoneyama R., Frangioni J.V., et al. Tracking stem cells in the cardiovascular system. Trends Cardiovasc Med 15 (2005) 297-302
40. Kalikin L.M., Schneider A., Thakur M.A., et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2 (2003) 656-660
41. LeRoy B.E., Thudi N.K., Nadella M.V., et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 66 (2006) 1213-1222
42. Brakenhielm E., Burton J.B., Johnson M., et al. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 121 (2007) 2153-2161
43. Min J.J., and Gambhir S.S. Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects. Gene Ther 11 (2004) 115-125
44. Figueiredo M.L., Kao C., and Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther 15 (2007) 1053-1064
45. Dobosy J.R., Roberts J.L., Fu V.X., et al. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177 (2007) 822-831
46. Li L.C. Epigenetics of prostate cancer. Front Biosci 12 (2007) 3377-3397
47. Ray P., Bauer E., Iyer M., et al. Monitoring gene therapy with reporter gene imaging. Semin Nucl Med 31 (2001) 312-320
48. Sato M., Johnson M., Zhang L., et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 8 (2003) 726-737
49. Iyer M., Salazar F.B., Wu L., et al. Bioluminescence imaging of systemic tumor targeting using a prostate-specific lentiviral vector. Hum Gene Ther 17 (2006) 125-132
50. Li H., Li J.Z., Helm G.A., et al. Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models. Biotechnol Appl Biochem 46 (2007) 179-184
51. Sato M., Johnson M., Zhang L., et al. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 11 (2005) 3743-3749
52. Johnson M., Sato M., Burton J., et al. Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: The advantage of a cell-specific transcriptional targeting approach. Mol Imaging 4 (2005) 463-472
53. Pantuck A.J., Berger F., Zisman A., et al. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol 168 (2002) 1193-1198
54. Siddiqui F., Barton K.N., Stricker H.J., et al. Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther 18 (2007) 312-322
55. Liu L., Kodibagkar V.D., Yu J.X., et al. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl beta-D-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse. Faseb J 21 (2007) 2014-2019
56. Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 (1995) 3439-3443
57. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62 (2002) 2999-3004
58. Masumori N., Thomas T.Z., Chaurand P., et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61 (2001) 2239-2249
59. Gao H., Ouyang X., Banach-Petrosky W., et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 101 (2004) 17204-17209
60. Wang S., Gao J., Lei Q., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209-221
61. Ellwood-Yen K., Graeber T.G., Wongvipat J., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 (2003) 223-238
62. Singh A.S., and Figg W.D. In vivo models of prostate cancer metastasis to bone. J Urol 174 (2005) 820-826
63. Xie X., Luo Z., Slawin K.M., et al. The EZC-prostate model: noninvasive prostate imaging in living mice. Mol Endocrinol 18 (2004) 722-732
64. Lyons S.K., Lim E., Clermont A.O., et al. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res 66 (2006) 4701-4707
65. Hsieh C.L., Xie Z., Liu Z.Y., et al. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 35 (2005) 293-304
66. Hsieh C.L., Xie Z., Yu J., et al. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 67 (2007) 685-691
67. Massoud T.F., Paulmurugan R., De A., et al. Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol 18 (2007) 31-37
68. Ilagan R., Pottratz J., Le K., et al. Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer. Cancer Res 66 (2006) 10778-10785
69. Kim S.B., Ozawa T., Watanabe S., et al. High-throughput sensing and noninvasive imaging of protein nuclear transport by using reconstitution of split Renilla luciferase. Proc Natl Acad Sci USA 101 (2004) 11542-11547
70. Ray P., De A., Min J.J., et al. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64 (2004) 1323-1330
71. Pomper M.G. Translational molecular imaging for cancer. Cancer Imaging 5 Spec No A (2005) S16-S26
72. Somia N., and Verma I.M. Gene therapy: trials and tribulations. Nat Rev Genet 1 (2000) 91-99
73. Yaghoubi S., Barrio J.R., Dahlbom M., et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 42 (2001) 1225-1234
74. Yaghoubi S.S., Couto M.A., Chen C.C., et al. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. J Nucl Med 47 (2006) 706-715
75. Jacobs A., Voges J., Reszka R., et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
76. Penuelas I., Mazzolini G., Boan J.F., et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1795
77. Lee K.C., Sud S., Meyer C.R., et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67 (2007) 3524-3528